Literature DB >> 31578993

A critique of the fragility index.

David Bomze1, Tomer Meirson2.   

Abstract

Year:  2019        PMID： 31578993     DOI： 10.1016/S1470-2045(19)30582-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Fragility index of network meta-analysis with application to smoking cessation data.

Authors:  Aiwen Xing; Haitao Chu; Lifeng Lin
Journal:  J Clin Epidemiol       Date:  2020-07-10       Impact factor: 6.437

2.  The fragility and reverse fragility indices of proximal humerus fracture randomized controlled trials: a systematic review.

Authors:  Peter William Kyriakides; Blake Joseph Schultz; Kenneth Egol; Philipp Leucht
Journal:  Eur J Trauma Emerg Surg       Date:  2021-05-31       Impact factor: 3.693

3.  The ellipse of insignificance, a refined fragility index for ascertaining robustness of results in dichotomous outcome trials.

Authors:  David Robert Grimes
Journal:  Elife       Date:  2022-09-20       Impact factor: 8.713

4.  Assessing and visualizing fragility of clinical results with binary outcomes in R using the fragility package.

Authors:  Lifeng Lin; Haitao Chu
Journal:  PLoS One       Date:  2022-06-01       Impact factor: 3.752

5.  Is There Already a Need of Reckoning on Cancer Immunotherapy?

Authors:  Pierpaolo Correale; Francesca Pentimalli; Giovanni Baglio; Marjia Krstic-Demonacos; Rita Emilena Saladino; Antonio Giordano; Luciano Mutti
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

6.  Factors that impact fragility index and their visualizations.

Authors:  Lifeng Lin
Journal:  J Eval Clin Pract       Date:  2020-06-10       Impact factor: 2.336

7.  Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors.

Authors:  David Bomze; Nethanel Asher; Omar Hasan Ali; Lukas Flatz; Daniel Azoulay; Gal Markel; Tomer Meirson
Journal:  JAMA Netw Open       Date:  2020-10-01

8.  Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.

Authors:  Brooke E Wilson; Alexandra Desnoyers; Michelle B Nadler; Ariadna Tibau; Eitan Amir
Journal:  Cancer Med       Date:  2021-07-28       Impact factor: 4.452
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.